Search clinical trials for: LHRH agonist

Total 13763 results

Astellas Pharma China, Inc.

Completed

A Study to Investigate the Effect of Food With Mirabegron in Healthy Chinese Participants

Pharmacokinetics of Mirabegron | Food Effect | Healthy Chinese Subjects

China
Swiss Group for Clinical Cancer Research

Completed

Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Myeloproliferative Neoplasm

Switzerland
CHU de Quebec-Universite Laval

Completed

Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder (Mirabegron)

Overactive Bladder | Urinary Incontinence
Mercy Research
Forest Laboratories

Completed

Effects of Nebivolol on Exercise Tolerance and Left Ventricular Systolic and Diastolic Function

Hypertension

United States
Astellas Pharma Inc

Completed

A Study of YM178 in Patients With Symptomatic Overactive Bladder

Urinary Bladder, Overactive

Japan
Mylan Bertek Pharmaceuticals

Completed

A Study of the Efficacy and Safety of Nebivolol Added to Existing Antihypertensive Treatment in Patients With Hypertension

Hypertension

United States
Wake Forest University Health Sciences
National Institute of Neurological Disorders and Stroke (NINDS)

Completed

Clonidine Versus Adenosine to Treat Neuropathic Pain

Pain

United States
Institute of Hematology & Blood Diseases Hospital
Henan Cancer Hospital; Nantong University; Tianjin Medical University Second... and other collaborators

Unknown

Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults

Primary Immune Thrombocytopenia (ITP)

China
Stanford University

Recruiting

The BIomarker Guided Study for Depression (BIG)

Major Depressive Disorder

United States
University of Alabama at Birmingham

Completed

The Effect of Guanfacine on Delirium in Critically Ill Patients

Delirium

United States
Theodore R. Brown, MD MPH
Astellas Pharma Inc

Completed

Study of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple Sclerosis (MIRROR)

Multiple Sclerosis

United States
Yale University
National Institute on Drug Abuse (NIDA); National Institute on Alcohol Abuse... and other collaborators

Completed

Modeling Stress-precipitated Smoking Behavior for Medication Development

Smoking

United States
Baylor College of Medicine

Completed

Mirabegron as Medical Expulsive Therapy (MET) for Ureteral Stones and Ureteral Stent Pain

Ureteral Obstruction | Flank Pain

United States
Assistance Publique - Hôpitaux de Paris
Association Française contre les Myopathies (AFM), Paris

Completed

Nebivolol for the Prevention of Left Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy (NEBIDYS)

Heart Failure | Duchenne Muscular Dystrophy | Cardiomyopathy

France
Actavis Inc.
Watson Laboratories, Inc.

Completed

Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea

Rosacea

United States
University of California, San Diego
Forest Laboratories

Completed

Effects of the Beta-blocker Nebivolol (Bystolic) on Subjects With High Normal Blood Pressure and/or a Family History of Hypertension

Hypertension | Pre-hypertension

United States
Galderma Brasil Ltda.
Eurotrials Brasil Consultores Cientificos Ltda

Completed

A Multicenter, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Once Daily Mirvaso® Gel in Patients With Chronic Persistent Vascular Facial Erythema. (BR14004)

Chronic Persistent Vascular Facial Erythema

Brazil
Buddhist Tzu Chi General Hospital

Completed

Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan

Urinary Incontinence | Overactive Bladder Syndrome
Astellas Pharma Inc
Astellas Pharma Taiwan, Inc.

Completed

A Study to Investigate the Safety and Effect of Food on the Pharmacokinetics of YM178 in Healthy Volunteers

Healthy Volunteer | Pharmacokinetics of YM178

Taiwan
Astellas Pharma Inc

Completed

A Study to Evaluate Absorption, Distribution and Elimination of Mirabegron After Oral Administration to Non-elderly Healthy Chinese Subjects

Healthy Subjects | Plasma Concentration of Mirabegron

Japan
Icahn School of Medicine at Mount Sinai

Unknown

Guanfacine to Treat Borderline Personality Disorder

Borderline Personality Disorder

United States
Jagiellonian University
University Hospital in Krakow

Not yet recruiting

Beta-blockade in Unruptured Intracranial Aneurysm (BBLURAN)

Intracranial Aneurysm

Poland
Philip Kern
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

Mechanisms for Activation of Beige Adipose Tissue in Humans

PreDiabetes

United States
Astellas Pharma China, Inc.

Completed

A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder

Urge Incontinence | Overactive Bladder (OAB)

China
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder

Overactive Bladder | Pharmacokinetics of Mirabegron | Neurogenic Detrusor Overactivity

Belgium, Denmark, Norway, Poland, Serbia
Astellas Pharma Global Development, Inc.

Completed

Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB) (PILLAR)

Overactive Bladder (OAB)

United States, Canada
Philadelphia Urosurgical Associates
Astellas Pharma Global Development, Inc.

Terminated

A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial Cystitis (MirabegronIC)

Cystitis, Interstitial

United States
Astellas Pharma Inc

Completed

A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (ARIES)

Urinary Bladder, Overactive

United States, Canada
Astellas Pharma Inc

Completed

A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (CAPRICORN)

Urinary Bladder, Overactive

United States, Hungary, Canada, Spain, Finland, Slovakia, Czechia, Sweden, Germany, Denmark, Norway
Massachusetts General Hospital
Forest Laboratories

Completed

Study to Evaluate Effect of Nebivolol on Angina in Women With Microvascular Disease (NIRVANA)

Microvascular Angina

United States
Medical University of Vienna

Withdrawn

Relation Between Intraocular Pressure Lowering Effects of Topical Brimonidine and Alpha 2 Receptor Polymorphism

Intraocular Pressure | Ocular Physiology

Austria
Astellas Pharma Inc

Completed

A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)

Lower Urinary Tract Symptoms | Bladder Outlet Obstruction

United States, Canada
Astellas Pharma Inc

Completed

A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment

Renal Impairment

United States
Central Hospital, Nancy, France

Unknown

Norepinephrine vs Norepinephrine and Dobutamine in Cardiogenic Shock (SHOCK-NORDOB)

Cardiogenic Shock

France
Jose Seijas Amigo

Completed

SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY. (SEVERAL)

Quality of Life | Diabetes Mellitus, Type 2 | Weight Loss | Safety Issues

Spain
Hospital de Clinicas de Porto Alegre

Unknown

Evaluation of Granulosa Cells Function After IVF Protocols

Infertility | In Vitro Fertilization Protocols

Brazil
Gruppo Italiano Malattie EMatologiche dell'Adulto

Unknown

Response Rate and Duration After Discontinuation Thrombopoietin Receptor Agonists Primary Immune Thrombocytopenia

Immune Thrombocytopenia

Italy
Astellas Pharma Inc

Completed

Specified Drug Use-results Survey of Betanis Tablets

Overactive Bladder

Japan
Otto Muzik

Unknown

Efficacy of Pharmacological Stimulation of BAT and WAT in Lean and Obese Young Adults (MiraBAT)

Brown Fat

United States
Astellas Pharma Inc

Completed

A Study to Investigate the Food Effect on the Pharmacokinetics of YM178 in Healthy, Non-elderly Volunteers

Healthy Volunteer | Pharmacokinetics of YM178

Japan
AstraZeneca

Completed

Evaluation of the Pharmacokinetics and the Pharmacodynamics of Different Dry Powder Inhalation Formulations of AZD3199 in Patients With Asthma

Asthma

Sweden
Alliance Foundation Trials, LLC.
Janssen Research & Development, LLC

Active, not recruiting

A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

Prostate Cancer

United States
Universitair Ziekenhuis Brussel

Unknown

Clinical Assessment of Arterial Dynamic Elastance in ICU Patients, Dependent on Inotropic or Vasopressor Drugs.

Sepsis | Cardiac Failure Acute

Belgium
National Institute of Mental Health (NIMH)

Recruiting

Effects of an ER Beta Agonist (Lilly Compound LY500307) on Estradiol-Withdrawal-Induced Mood Symptoms in Women With Past Perimenopausal Depression

Perimenopause-Related Depression

United States
Istituto Clinico Humanitas

Completed

RESCUE PROTOCOL AND FRESH EMBRYO TRANSFER

GnRH Trigger and Rescue Protocol
University of California, San Diego

Recruiting

ADRB3 Signaling Pathway in Human Adipose Tissue

Obesity, Prediabetes

United States
Ain Shams University

Recruiting

Evaluating the Outcome of Cardio Selective beta1- Blockers Use in Patients With Copd

Copd

Egypt
National Taiwan University Hospital

Completed

Predictors for Retreatement of OAB After DC Mirabegron

Recurrence of Overactive Bladder Syndrome

Taiwan
Astellas Pharma Inc

Completed

Long-Term Specified Drug Use-results Survey of Betanis Tablets

Overactive Bladder

Japan
Rochester Center for Behavioral Medicine
Shire

Completed

Efficacy and Safety Eval of Guanfacine Hydrochloride in Combination With Psychostimulants in Adults (18-65). (ADINT2012)

Adult Attention-Deficit Hyperactivity Disorder

United States

Search clinical trials for: LHRH agonist

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Indonesia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations